BioCentury
ARTICLE | Clinical News

BCY completes Phase II cystic fibrosis trial

August 7, 2003 7:00 AM UTC

BCY LifeSciences (TSE:BCY) completed enrollment in a Canadian Phase II trial of DCF 987 inhaled mucolytic dextran agent to treat cystic fibrosis (CF). The double-blind, placebo-controlled study is des...